Evidence map›Paper›PMID 29696431›Full record

ArticleEuropean radiology2018

Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.

Sangeet Ghai, Nathan Perlis, Uri Lindner, Eugen Hlasny, Masoom A Haider, Antonio Finelli, Alexandre R Zlotta, Girish S Kulkarni, Theodorus H van der Kwast, Stuart A McCluskey and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Frontiers of Ultrasound Technology in Prostate Cancer Treatment.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Heating technology for malignant tumors: a review.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Sangeet GhaiToronto Joint Department of Medical Imaging, University Health Network - Mt Sinai Hospital - Women's College Hospital, University of Toronto, Toronto, ON, Canada. Sangeet.ghai@uhn.ca.ORCID http://orcid.org/0000-0001-9451-0594
Nathan PerlisDivision of Urology, Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada.
Uri LindnerDivision of Urology, Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada.
Eugen HlasnyToronto Joint Department of Medical Imaging, University Health Network - Mt Sinai Hospital - Women's College Hospital, University of Toronto, Toronto, ON, Canada.
Masoom A HaiderToronto Joint Department of Medical Imaging, University Health Network - Mt Sinai Hospital - Women's College Hospital, University of Toronto, Toronto, ON, Canada.
Antonio FinelliDivision of Urology, Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada.
Alexandre R ZlottaDivision of Urology, Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada.
Girish S KulkarniDivision of Urology, Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada.
Theodorus H van der KwastLaboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada.
Stuart A McCluskeyDepartment of Anaesthesia, University Health Network, University of Toronto, Toronto, ON, Canada.
Walter KucharczykToronto Joint Department of Medical Imaging, University Health Network - Mt Sinai Hospital - Women's College Hospital, University of Toronto, Toronto, ON, Canada.
John TrachtenbergDivision of Urology, Department of Surgery, University Health Network, University of Toronto, Toronto, ON, Canada.
University Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the feasibility and safety of focal therapy for low-intermediate risk prostate cancer (PCa) with magnetic resonance-guided high frequency focused ultrasound (MRgFUS)

methodsThis IRB-approved phase 1 prospective study enrolled eight patients with prostate specific antigen (PSA) ≤ 10 ng/ml, ≤ cT2a and Gleason score ≤ 7 (4 + 3) disease following informed consent. Under MRI guidance, focused high frequency ultrasound energy was delivered to ablate the target tissue. Treatment-related adverse events were recorded. Oncologic outcomes were evaluated with multiparametric MRI, PSA and TRUS biopsy at 6 months following treatment.

resultsTen target lesions [six Gleason 6 lesions, two Gleason 7 (3 + 4) and two Gleason 7 (4 + 3)] were treated in eight men (prostate volume range, 25-50 cc; mean MRI time, 248 min per patient; mean sonication duration, 65 min). Mean target volume was 2.7 cc and mean post-treatment non-perfused volume was 4.3 cc. Quality of life parameters were similar between baseline and 6 months in 6/8 patients. All treated regions were negative on MRI; 4/8 patients and 6/10 target lesions (60%) were clear of disease on biopsy. One patient with 2-mm Gleason 8 disease in one of five cores from treatment site (4 + 3 disease at baseline) subsequently underwent prostatectomy with negative surgical margins. Three patients with low volume (5-15%) Gleason 6 residual disease were offered active surveillance. Mean PSA decreased from 5.06 at baseline to 3.4 ng/ml at 6 months.

conclusionMRgFUS is a feasible and safe method of noninvasively ablating low-intermediate risk PCa with acceptable short-term oncologic outcomes. KEY POINTS: • Focal therapy selectively ablates locally confined, clinically significant index lesion with a margin while sparing rest of gland and adjacent vital structures. • Magnetic resonance-guided focused high frequency ultrasound surgery (MRgFUS) combines MRI with HIFU. • MRgFUS provides ability to monitor treatments in real time and allows a targeted approach for focal ablation. • MRgFUS is a feasible, safe method of noninvasively ablating low-intermediate risk PCa. • MRgFUS provides acceptable oncologic outcomes at 6 months.

Indexed as

AgedHigh-Intensity Focused Ultrasound AblationHumansMagnetic Resonance Imaging, InterventionalMaleMiddle AgedNeoplasm GradingProspective StudiesProstatectomyProstatic NeoplasmsQuality of LifeSurgery, Computer-AssistedUltrasonographyHigh-intensity focused ultrasound ablationImage-guided surgeryInterventional magnetic resonance imagingMagnetic resonance imagingProstate cancer

Identifiers

PMID29696431
OpenAlexW2800175760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.